Septerna (SEPN) Consolidated Net Income (2023 - 2026)
Septerna's quarterly Consolidated Net Income came in at -$8.6 million in Q1 2026, up 59.78% year-on-year from -$5.4 million in Q1 2025, and up 19.57% quarter-over-quarter from -$10.7 million in Q4 2025.
Septerna has reported Consolidated Net Income for 4 years, with the latest figure at -$8.6 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 59.78% year-over-year to -$8.6 million; the trailing twelve-month figure through Mar 2026 stood at -$36.0 million (up 54.57% YoY), and the FY2025 full-year result was -$48.9 million, up 31.92% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$8.6 million, up from -$10.7 million in the prior quarter.
- The five-year high for Consolidated Net Income was $8.2 million in Q3 2025, with the low at -$24.8 million in Q2 2025.
- Average Consolidated Net Income over 4 years is -$14.4 million, with a median of -$16.7 million recorded in 2024.
- Year-over-year, Consolidated Net Income sank 87.51% in 2024 and surged 139.82% in 2025.
- Tracing SEPN's Consolidated Net Income over 4 years: stood at -$18.2 million in 2023, then dropped by 13.85% to -$20.7 million in 2024, then surged by 48.05% to -$10.7 million in 2025, then gained by 19.57% to -$8.6 million in 2026.
- The last three Consolidated Net Income figures came in at -$8.6 million (Q1 2026), -$10.7 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.74 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.67 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.66 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -18.15 Mn |
| Sep 30, 2023 | -10.95 Mn |